Bin Xi

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.

Zensun (Shanghai) Sci & Tech Co., Ltd. engages in the research and development of biopharmaceutical products. It offers recombinant protein, Neucardin, for chronic heart failure treatment. It also develops medicine for functional constipation, Alzheimer’s disease, and recurrent urinary tract infection treatment. The company was founded by Ming Dong Zhou and Xi Fu Liu on April 20, 2000 and is headquartered in Shanghai, China.